Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Journal of Clinical Rehabilitative Tissue Engineering Research》 2007-16
Add to Favorite Get Latest Update

Interleukin-2-receptor monoclonal antibody for prevention of acute rejection after renal transplantation

Xiong ZH,Lin Z,Chen J,Zhang YB,Hu ZX,Zhang Y.Department of Urinary Surgery,Anhui General Forces Hospital,Chinese People's Armed Police Forces,Hefei 230041,Anhui Province,China  
AIM:To observe the effect of interleukin 2 receptor monoclonal antibody(Simulect)in the prevention of acute rejection after renal transplantation.METHODS:Totally 47 renal transplantation recipients were enrolled from Anhui General Forces Hospital,Chinese People's Armed Police Forces from January 2004 to December 2005.The patients all agreed to participate into the trial.According to whether using Simulect or not,there were 2 groups,Simulect group in 25 cases and control group in 22 cases,who were not treated with Simulect.Each group received the same immunosuppressive therapy regimen consisted of cyclosporine,mycophenolate and prednisone(CsA+MMF+Pred).On this basis,the Simulect group received 20 mg Simulect at hour 2 before operation and day 4 after operation.Acute rejection,drug adverse reaction and complication were observed 6 months after operation.The recovery of renal function was evaluated by detecting creatinine level in serum.RESULTS:Totally 47 patients were involved in the result analysis,no drop-out.①incidence rate of acute rejection in patients of the two groups:It was significantly lower in the Simulect group than the control group(12%,41%,P 0.05).②adverse reaction and complication in patients of the two groups:There were pulmonary infection in 2 cases,liver functional lesion in 1 case and gastrointestinal tract reaction in 6 cases in the Simulect group,as well as pulmonary infection in 2 cases,liver functional lesion in 3 cases and gastrointestinal tract reaction in 4 cases in the control group.There was no significant difference between the two groups(P 0.05).No complication occurred in the two groups such as hypolekocytosis,incision infection,urinary tract infection,hyperglycemia and so on.③creatinine level in serum in patients of the two groups:At weeks 1 and 2,it was lower in the Simulect group than the control group [(104.7±10.1),(103.1±7.7);(128.3±28.2),(120.0±8.5)μmol/L(P 0.05)].From month 1-6 after operation,there was no significant difference in creatinine level in serum between the two groups(P 0.05).It indicated that in the two groups the renal function recovered normally 2 weeks after operation.CONCLUSION:As a safe and effective induction therapy drug,simulect which seldom cause adverse reactions can prevent acute rejection in renal transplantation recipients.
【CateGory Index】: R699
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved